192 related articles for article (PubMed ID: 17879629)
1. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
Rehnberg J; Zendehrokh N; Dejmek A
Anal Quant Cytol Histol; 2007 Aug; 29(4):217-20. PubMed ID: 17879629
[TBL] [Abstract][Full Text] [Related]
2. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions.
Schönherr A; Bayer M; Böcking A
Cell Oncol; 2004; 26(1-2):57-62. PubMed ID: 15371657
[TBL] [Abstract][Full Text] [Related]
6. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
8. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
Kimura F; Kawamura J; Watanabe J; Kamoshida S; Kawai K; Okayasu I; Kuwao S
Diagn Cytopathol; 2010 Mar; 38(3):161-7. PubMed ID: 19821496
[TBL] [Abstract][Full Text] [Related]
9. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
11. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
13. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.
Davidson B; Risberg B; Berner A; Nesland JM; Tropé CG; Kristensen GB; Bryne M; Goscinski M; van de Putte G; Flørenes VA
Gynecol Oncol; 2001 Nov; 83(2):249-56. PubMed ID: 11606079
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
Ferrandez-Izquierdo A; Navarro-Fos S; Gonzalez-Devesa M; Gil-Benso R; Llombart-Bosch A
Diagn Cytopathol; 1994; 10(3):256-62. PubMed ID: 7519540
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
16. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
17. The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells.
Lv M; Cha N; Zou YF; Leng JH; Hao YY; Wang S
Diagn Cytopathol; 2021 Jul; 49(7):811-816. PubMed ID: 33818924
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
19. The importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions.
Sadullahoglu C; Nart D; Veral A
Diagn Cytopathol; 2017 Feb; 45(2):118-124. PubMed ID: 28024110
[TBL] [Abstract][Full Text] [Related]
20. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
